Elenestinib
- Generic Name
- Elenestinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29FN10O
- CAS Number
- 2505078-08-8
- Unique Ingredient Identifier
- 6FBM4CP6RK
- Background
Elenestinib is a selective KIT inhibitor.
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Phase 1
Terminated
- Conditions
- Advanced Systemic Mastocytosis
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT05609942
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪University Medical Centre Mannheim, Mannheim, Germany
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Phase 2
Recruiting
- Conditions
- Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 534
- Registration Number
- NCT04910685
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Virgen del Valle - Instituto de Estudios de Mastocitosis de Castilla-La Mancha, Toledo, Spain
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath